Status:
RECRUITING
Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy
Lead Sponsor:
Duke University
Conditions:
BRCA1 Mutation
BRCA2 Mutation
Eligibility:
FEMALE
19-50 years
Phase:
NA
Brief Summary
The goal of this study is to develop an educational aid about hormone replacement therapy that physicians can share with patients as part of their pre-surgical counseling for a risk-reducing salpingo-...
Detailed Description
The proposed randomized study seeks to enroll 50 individuals from gynecologic oncology and high-risk breast clinics who are actively planning RRSO. Participants will be randomized to usual provider ed...
Eligibility Criteria
Inclusion
- BRCA1 or BRCA2 germline mutation
- scheduled for a risk-reducing salpingo-oophorectomy (RRSO) by Duke Gynecologic Oncologist
- premenopausal
Exclusion
- personal history of cancer
- postmenopausal
- \>50 years old
- unable to provide informed consent in English
Key Trial Info
Start Date :
September 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06972719
Start Date
September 30 2025
End Date
December 31 2026
Last Update
October 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University Health System
Durham, North Carolina, United States, 27710